A F Sabato1, G Marineo, A Gatti. 1. Anesthesiology and Resuscitation Unit, Service of Physiopathology and Therapy of Pain, Department of Emergency, Tor Vergata University, Rome, Italy. sabato@med.uniroma2.it
Abstract
UNLABELLED: In neuropathies there are complex reactions that modify the homeostatic equilibrium of pain system. In such a context the Scrambler Therapy (ST5) interferes with pain signal transmission, by ''mixing'' a ''non-pain'' information into the nerve fibres. The aim of this study is to evaluate the effectiveness of ST5 in the treatment of neuropathic pain. The ST5 consists of a multiprocessor apparatus able to simulate 5 artificial neurons by the application of surface electrodes on skin pain areas. A total of 226 patients, all suffering from intense drug-resistant neuropathic pain, were recruited for this trial in 2004. INCLUSION CRITERIA: neuropathic pain, very high baseline visual analogue scale (VAS). EXCLUSION CRITERIA: pacemaker users, neurolithic blocks or neurolesive pain control treatment. The treated neuropathic pain syndromes were: failed back surgery syndrome (FBSS), sciatic and lumbar painpost-herpetical (PHN), trigeminal neuralgia, post-surgery nerve lesion neuropathy, pudendal neuropathy, brachial plexus neuropathy, low back pain (LBP), others. The trial programme: 1 to 6 therapy sessions of 5 treatments, each one lasting 30 min. Pain intensity was evaluated using VAS before and after each treatment. The statistical significance of VAS was measured using the paired t-test. The total results show 80.09% of responders (pain relief>50%), 10.18% of partially responders (pain relief from 25% to 49%) and 9.73% of no responders (patients with pain relief<24% or VAS>3). The CONCLUSIONS: is draen that ST5 produced a statistically significant (P<0.0001) pain relief in all treated neuropathies.
UNLABELLED: In neuropathies there are complex reactions that modify the homeostatic equilibrium of pain system. In such a context the Scrambler Therapy (ST5) interferes with pain signal transmission, by ''mixing'' a ''non-pain'' information into the nerve fibres. The aim of this study is to evaluate the effectiveness of ST5 in the treatment of neuropathic pain. The ST5 consists of a multiprocessor apparatus able to simulate 5 artificial neurons by the application of surface electrodes on skin pain areas. A total of 226 patients, all suffering from intense drug-resistant neuropathic pain, were recruited for this trial in 2004. INCLUSION CRITERIA: neuropathic pain, very high baseline visual analogue scale (VAS). EXCLUSION CRITERIA: pacemaker users, neurolithic blocks or neurolesive pain control treatment. The treated neuropathic pain syndromes were: failed back surgery syndrome (FBSS), sciatic and lumbar painpost-herpetical (PHN), trigeminal neuralgia, post-surgery nerve lesion neuropathy, pudendal neuropathy, brachial plexus neuropathy, low back pain (LBP), others. The trial programme: 1 to 6 therapy sessions of 5 treatments, each one lasting 30 min. Pain intensity was evaluated using VAS before and after each treatment. The statistical significance of VAS was measured using the paired t-test. The total results show 80.09% of responders (pain relief>50%), 10.18% of partially responders (pain relief from 25% to 49%) and 9.73% of no responders (patients with pain relief<24% or VAS>3). The CONCLUSIONS: is draen that ST5 produced a statistically significant (P<0.0001) pain relief in all treated neuropathies.
Authors: Marianna Ricci; Sara Pirotti; Emanuela Scarpi; Marco Burgio; Marco Maltoni; Elisabetta Sansoni; Dino Amadori Journal: Support Care Cancer Date: 2011-05-06 Impact factor: 3.603
Authors: Charles Loprinzi; Jennifer G Le-Rademacher; Neil Majithia; Ryan P McMurray; Carrie R O'Neill; Markus A Bendel; Andreas Beutler; Daniel H Lachance; Andrea Cheville; David M Strick; David F Black; Jon C Tilburt; Thomas J Smith Journal: Support Care Cancer Date: 2019-06-17 Impact factor: 3.603
Authors: Maureen A Mealy; Sharon L Kozachik; Lawrence J Cook; Lauren Totonis; Ruth Andrea Salazar; Jerilyn K Allen; Marie T Nolan; Thomas J Smith; Michael Levy Journal: Neurology Date: 2020-04-08 Impact factor: 9.910
Authors: Deirdre R Pachman; Breanna L Weisbrod; Drew K Seisler; Debra L Barton; Kelliann C Fee-Schroeder; Thomas J Smith; Daniel H Lachance; Heshan Liu; Randy A Shelerud; Andrea L Cheville; Charles L Loprinzi Journal: Support Care Cancer Date: 2014-09-24 Impact factor: 3.603